×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Regeneron reveals potential delay for Dupixent in COPD, stagnant sales for Eylea
Fierce Pharma
Sanofi and Regeneron's highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be delayed,...
2 days ago
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Yahoo Finance
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
2 days ago
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters
U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its...
2 days ago
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
markets.businessinsider.com
Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 16 analysts in the last quarter, revealing a spectrum of viewpoints from...
1 day ago
Regeneron, Lilly grapple with clinical endpoints as obesity space moves to improving weight loss
Fierce Biotech
The next frontier in obesity is improving the quality of weight loss. As combo drugs inch closer to phase 3, what will the FDA want as an...
2 days ago
Regeneron Reverses On Better-Than-Feared Eylea Sales
Investor's Business Daily
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
1 day ago
Regeneron reports Q1 adjusted EPS $9.55, consensus $10.10 - TipRanks.com
Tipranks
Reports Q1 revenue $3.15B, consensus $3.22B. “The Regeneron team has already made substantial progress this year, delivering our approved...
1 day ago
Regeneron stock falls despite $3B buybacks (NASDAQ:REGN)
Seeking Alpha
Regeneron Pharmaceuticals (REGN) stock falls despite a $3B in share buyback program as the company missed forecasts with its Q1 2024 results...
2 days ago
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation - Regeneron Pharmaceuticals ...
Benzinga
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets.
1 day ago
Regeneron builds new venture arm with $500M commitment
Fierce Biotech
Regeneron's new venture arm, Regeneron Ventures, will be led by two of the pharma's former execs.
3 weeks ago